N/A N=31 VLU Dressing Study
Venous Leg Ulcer
Primary: Change in Bacterial Load — 12678.81; 33190.8 CFU/gram
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=80 Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia
Pregnancy Related · Anemia, Iron Deficiency
Primary: Median Change in Hemoglobin Value Before and After Intervention — 10.95; 11.45 g/dL — p=< 0.001
Phase 1 N=28 A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
Obesity
Primary: Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) — 0.0; 83.3; 0.0; 85.7 Percentage of participants
Phase 2 N=34 Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Leukemia · Myelodysplastic Syndromes · Childhood Acute Myeloid Leukemia in Remission
Primary: Incidence of Engraftment — 100; 93; 100 Percentage of participants
N/A N=3,431 Emp-Activity: Empagliflozin Functional Capacity
Heart Failure
Primary: Change of the Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores in Patients Newly Treated With Empagliflozin According to Routine Practice — 14.66; 17.61; 16.47…
Phase 1 N=42 Phase 1 Study of SAR440894 vs Placebo
Chikungunya Virus Infection
Primary: Frequency of Adverse Events (AEs) — 5; 3; 2; 3 Participants
N/A N=1,216 Preventing Drug Abuse Among Sexual Minority Youth
Substance Abuse
Primary: Average Number of Times Youth Drank Alcohol in the Past Month — 0.83; 1.03 number of times
Phase 3 N=695 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: 3 Years Event-free Survival — 51; 56; 126; 123 Participants
Phase 3 N=1,085 A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -1.68; -1.31 Percentage of HbA1c — p=<0.0001
N/A N=50 Minimally Invasive Burch Colposuspension to Reduce Occult Stress Incontinence
Pelvic Organ Prolapse · Urinary Incontinence,Stress · Urinary Incontinence, Urge
Primary: Number of Participants With Stress Urinary Incontinence — 10; 13 Participants
Phase 2 N=143 A Study of IVX-A12 in Adults Participants
Healthy Participants
Primary: Model-adjusted Geometric Mean Concentration (GMC) for RSV/A Neutralizing Antibodies (NAb) — 5910.4; 10500.4 internation unit per milliliter (IU/mL)
N/A N=50 The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting
Non-Alcoholic Fatty Liver Disease
Primary: Serum Markers (sfG) to Follow the Evolution of Liver Damage — 22.59; 28.51; 38.59; 21.34 U/L
Phase 1 N=29 ED Initiated Oral Naltrexone for AUD
Alcohol Use Disorder
Primary: Number of Participants Enrolled and Receiving Formal Addiction Treatment at Day 14 — 6; 15 Participants
N/A N=499 ClotTriever Outcomes (CLOUT) Registry
Deep Vein Thrombosis Leg · DVT · Chronic DVT of Lower Extremity
Primary: Primary Safety Endpoint: Proportion Participants With Major Adverse Events — 15 Participants
N/A N=48 Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.
Smoking · Abdominal Aortic Aneurysm · IQOS Use
Primary: AAA Annual Growth Rate Over Time — 1.80; 1.87; 1.27 (mm/year)